The evolving role of diffusion magnetic resonance imaging in movement disorders

Current Neurology and Neuroscience Reports

Volumn 13, Issue 11, 2013, Pages

  Hess, Christopher W ^a,b   Ofori, Edward ^a   Akbar, Umer ^a   Okun, Michael S ^a   Vaillancourt, David E ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diffusion magnetic resonance imaging; Diffusion tensor imaging; Dystonia; Essential tremor; Huntington's disease; Movement disorders; Parkinson's disease; Parkinsonism

Indexed keywords

ARTICLE; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DYSTONIA; ESSENTIAL TREMOR; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; TORTICOLLIS; TRACTOGRAPHY; VOXEL BASED MORPHOMETRY; WRITER'S CRAMP; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; MOVEMENT DISORDERS; TRENDS; UTILIZATION; REVIEW; UTILIZATION REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MOVEMENT DISORDERS;

EID: 84883783248     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0400-1     Document Type: Article

References (107)

1. Scherfler C, Schocke MF, Seppi K, Esterhammer R., Brenneis C, Jaschke W, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brai (Pubitemid 43164375)
2. Stoessl AJ, Brooks DJ, Eidelberg D. Milestones in neuroimaging. Mov Disord. 2011; 26(6): 868-978. doi: 10.1002/mds.23679.
3. Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron. 2006; 51(5): 527-39. doi: 10.1016/j.neuron.2006.08.012. (Pubitemid 44301829)
4. Prodoehl J, Li H, Planetta P.J., Goetz CG, Shannon KM, Tangonan R, et al. Diffusion tensor imaging of Parkinson's disease, atypical Parkinsonism, and essential tremor. Mov Disord. 2013. doi: 10.1002/mds.25491. This study used a multitargeted approach using basal ganglia and cerebellar ROI to study the discriminative capability of diffusion MRI in patients with PD, MSA-P, PSP, and ETand healthy controls. Excellent differentiation was achieved between the differentiation of diseases from each other and from controls, and the pattern of diffusion MRI targets and measures was unique for each disease.
5. Zheng Z, Shemmassian S, Wijekoon C., Kim W, Bookheimer SY, Pouratian N. DTI correlates of distinct cognitive impairments in Parkinson's disease. Hum Brain Mapp. 2013. doi: 10.1002/hbm.22256.
6. Saini J, Bagepally BS, Bhatt M.D., Chandran V., Bharath RD, Prasad C, et al. Diffusion tensor imaging: tract based spatial statistics study in essential tremor. Parkinsonism Relat Disord. 2012; 18(5): 477-82. doi: 10.1016/j.parkreldis.2012.01.006.
7. Argyelan M, Carbon M, Niethammer M., Ulug AM, Voss HU, Bressman SB, et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci. 2009; 29(31): 9740-7. doi: 10. 1523/JNEUROSCI.2300-09.2009.
8. Wang HC, Hsu JL, Leemans A. Diffusion tensor imaging of vascular parkinsonism: structural changes in cerebral white matter and the association with clinical severity. Arch Neurol. 2012; 69(10): 1340-8. doi: 10.1001/archneurol.2012.633.
9. Zhang K, Yu C, Zhang Y., Wu X, Zhu C, Chan P., et al. Voxel-based analysis of diffusion tensor indices in the brain in patients with Parkinson's disease. Eur J Radiol. 2011; 77(2): 269-73. doi: 10. 1016/j.ejrad.2009.07.032.
10. Jones DK, Knosche TR, Turner R. White matter integrity, fiber count, and other fallacies: the do's and don'ts of diffusion MRI. Neuroimage. 2013; 73: 239-54. doi: 10.1016/j.neuroimage.2012.06.081.
11. Soares JM, Marques P, Alves V., Sousa N. A hitchhiker's guide to diffusion tensor imaging. Front Neurosci. 2013; 7: 31. doi: 10.3389/fnins.2013. 00031.
12. Blood AJ, Kuster JK, Woodman S.C., Kirlic N., Makhlouf ML, Multhaupt-Buell TJ, et al. Evidence for altered basal ganglia-brainstem connections in cervical dystonia. PloS One. 2012; 7(2): e31654. doi: 10.1371/journal.pone.0031654.
13. Zhan W, Kang GA, Glass G.A., Zhang Y., Shirley C, Millin R, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord. 2012; 27(1): 90-7. doi: 10.1002/mds.23917.
14. Prakash BD, Sitoh YY, Tan L.C., Au WL. Asymmetrical diffusion tensor imaging indices of the rostral substantia nigra in Parkinson's disease. Parkinsonism Relat Disord. 2012; 18(9): 1029-33. doi: 10. 1016/j.parkreldis. 2012.05.021.
15. Planetta PJ, Schulze ET, Geary E.K., Corcos DM, Goldman JG, Little DM, et al. Thalamic projection fiber integrity in de novo Parkinson disease. AJNR Am J Neuroradiol. 2013; 34(1): 74-9. doi: 10.3174/ajnr.A3178.
16. Agosta F, Kostic VS, Davidovic K, Kresojevic N., Sarro L, Svetel M, et al. White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations. Mov Disord. 2013; 28(6): 772-8. doi: 10.1002/mds.25397.
17. Du G, Lewis MM, Sen S, Wang J., Shaffer ML, Styner M, et al. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord. 2012; 27(13): 1636-43. doi: 10.1002/mds. 25182.
18. Sharman M, Valabregue R, Perlbarg V., Marrakchi-Kacem L, Vidailhet M, Benali H., et al. Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. Mov Disord. 2013; 28(4): 447-54. doi: 10.1002/mds.25255.
19. Carlesimo GA, Piras F, Assogna F., Pontieri FE, Caltagirone C, Spalletta G Hippocampal abnormalities and memory deficits in Parkinson disease: A multimodal imaging study. Neurology. 2012; 78(24): 1939-45. doi: 10.1212/WNL0b013e318259e1c5.
20. Rae CL, Correia MM, Altena E, Hughes L.E., Barker RA, Rowe JB. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage. 2012; 62(3): 1675-84. doi: 10.1016/j.neuroimage.2012.06.012.
21. Deng B, Zhang Y, Wang L., Peng K Han L, Nie K et al. Diffusion tensor imaging reveals white matter changes associated with cognitive status in patients with Parkinson's disease. Am J Alzheimers Dis Other Demen. 2013; 28(2): 154-64. doi: 10.1177/1533317512470207.
22. Surdhar I, Gee M, Bouchard T., Coupland N, Malykhin N, Camicioli R. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. Parkinsonism Relat Disord. 2012; 18(7): 809-13. doi: 10.1016/j. parkreldis.2012.03.008.
23. Gallagher C, Bell B, Bendlin B., Palotti M, Okonkwo O, Sodhi A., et al. White matter microstructural integrity and executive function in Parkinson's disease. JIntNeuropsycholSoc. 2013; 19(3): 349-54. doi: 10.1017/ S1355617712001373.
24. Kamagata K, Motoi Y, Tomiyama H., Abe O, Ito K, Shimoji K., et al. Relationship between cognitive impairment and white-matter alteration in Parkinson's disease with dementia: tract-based spatial statistics and tract-specific analysis. Eur Radiol. 2013. doi: 10.1007/s00330-013-2775-4.
25. Ford AH, Duncan GW, Firbank M.J., Yarnall AJ, Khoo TK, Burn DJ, et al. Rapid eye movement sleep behavior disorder in Parkinson's disease: Magnetic resonance imaging study. Mov Disord Off J Mov Disord Soc. 2013; 23(7): 1946-55. doi: 10.1002/mds.25367.
26. Tsukamoto K, Matsusue E, Kanasaki Y., Kakite S, Fujii S, Kaminou T., et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. Neuroradiology. 2012; 54(9): 947-55.
27. Agosta F, Pievani M, Svetel M., Jecmenica Lukic M, Copetti M, Tomic A., et al. Diffusion tensor MRI contributes to differentiate Richardson's syndrome from PSP-parkinsonism. Neurobiol Aging. 2012; 33(12): 2817-26. doi: 10.1016/j.neurobiolaging.2012.02.002.
28. Haller S, Badoud S, Nguyen D., Garibotto V, Lovblad KO, Burkhard PR. Individual detection of patients with Parkinson disease using support vector machine analysis of diffusion tensor imaging data: initial results. AJNR Am J Neuroradiol. 2012; 33(11): 2123-8. doi: 10.3174/ajnr.A3126.
29. Nair SR Tan LK, Mohd Ramli N, Lim SY, Rahmat K, Mohd Nor H. A decision tree for differentiating multiple system atrophy from Parkinson's disease using 3-T MR imaging. Eur Radiol. 2013. doi: 10.1007/s00330-012-2759-9.
30. Whitwell JL, Xu J, Mandrekar J., Gunter JL, Jack Jr CR, Josephs KA. Imaging measures predict progression in progressive supranuclear palsy. Mov Disord. 2012; 27(14): 1801-4. doi: 10.1002/mds.24970.
31. Saini J, Bagepally BS, Sandhya M, Pasha S.A., Yadav R., Pal PK. In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS. Neuroradiology. 2012; 54(7): 771-80. doi: 10.1007/s00234-011- 0983-7.
32. Lu CF, Soong BW, Wu H.M., Teng S., Wang PS, Wu YT. Disrupted cerebellar connectivity reduces whole-brain network efficiency in multiple system atrophy. Mov Disord. 2013; 28(3): 362-9. doi: 10. 1002/mds.25314.
33. Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in Parkinsonian syndromes: A systematic review and meta-analysis. Neurology. 2013; 80(9): 857-64. doi: 10.1212/WNL. 0b013e318284070c. This systematic review and meta-analysis describes many of the important diffusion MRI studies that predated those described in Table 1 and describes a significant effect size for decreased FA in the SN in PD patients compared with controls.
34. Sherer TB. Biomarkers for Parkinson's disease. Sci Transl Med. 2011; 3(79): 79ps14. doi: 10.1126/scitranslmed.3002488.
35. Menke RA, Scholz J, Miller K.L., Deoni S., Jbabdi S, Matthews PM, et al. MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study. Neuroimage. 2009; 47(2): 435-41. doi: 10.1016/j.neuroimage.2009.05.017.
36. Menke RA, Jbabdi S, Miller K.L., Matthews PM, Zarei M. Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease. Neuroimage. 2010; 52(4): 1175-80. doi: 10.1016/j. neuroimage.2010.05.086.
37. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I., Corcos DM, Zhou XJ, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009; 72(16): 1378-84. doi: 10.1212/01.wnl.0000340982.01727.6e.
38. Vaillancourt DE, Spraker MB, Prodoehl J, Zhou X.J., Little DM. Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. Neurobiol Aging. 2012; 33(1): 35-42. doi: 10.1016/j.neurobiolaging. 2010.02.006.
39. Boska MD, Hasan KM, Kibuule D, Banerjee R., McIntyre E, Nelson JA, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis. 2007; 26(3): 590-6. doi: 10.1016/j.nbd.2007.02.010. (Pubitemid 46756326)
40. Skorpil M, Soderlund V, Sundin A., Svenningsson P. MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra. J Park Dis. 2012; 2(2): 171-80. doi: 10.3233/JPD-2012-12091.
41. Martin WR, Wieler M, Gee M. Mdbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology. 2008; 70(16 Pt 2): 1411-7. doi: 10.1212/01.wnl.0000286384.31050.b5. (Pubitemid 351521933)
42. z.ast; imaging and showed abnormalities in both measures in the SN, with combined measures showing the greatest sensitivity and specificity in distinguishing patients from controls. Further, the two measures were not correlated, suggesting they might represent different pathological processes in PD.
43. Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. 2nd ed. Edinburgh: Saunders; 2011.
44. Horovitz SG, Ford A, Najee-Ullah MA, Ostuni J.L., Hallett M. Anatomical correlates of blepharospasm. Transl Neurodegener. 2012; 1(1): 12. doi: 10.1186/2047-9158-1-12.
45. van der Meer JN, Beukers RJ, van der Salm SM, Caan MW, Tijssen MA, Nederveen AJ. White matter abnormalities in gene-positive myoclonus-dystonia. Mov Disord. 2012; 27(13): 1666-72. doi: 10. 1002/mds.25128.
46. Cheng FB, Wan XH, Feng J.C., Ma LY, Hou B, Feng F, et al. Subcellular distribution of THAP1 and alterations in the micro structure of brain white matter in DYT6 dystonia. Parkinsonism Relat Disord. 2012; 18(8): 978-82. doi: 10.1016/j. parkreldis.2012.05.008.
47. Delmaire C, Dumas EM, Sharman M.A., van den Bogaard SJ, Valabregue R, Jauffret C, et al. The structural correlates of functional deficits in early Huntington's disease. Hum Brain Mapp. 2012; 34(9): 2141-53. doi: 10.1002/hbm.22055.
48. Di Paola M., Luders E, Cherubini A., Sanchez-Castaneda C, Thompson PM, Toga A.W., et al. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. Cereb Cortex. 2012; 22(12): 2858-66. doi: 10.1093/cercor/bhr360.
49. Van Camp N., Blockx I, Camon L., de Vera N, Verhoye M, Veraart J., et al. A complementary diffusion tensor imaging (DTI)-histological study in a model of Huntington's disease. Neurobiol Aging. 2012; 33(5): 945-59. doi: 10.1016/j.neurobiolaging.2010.07.001.
50. Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, et al. Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum Brain Mapp. 2012; 33(1): 203-12. doi: 10.1002/hbm.21205.
51. Georgiou-Karistianis N., Gray MA, Dominguez D.J., Dymowski AR Bohanna I, Johnston LA, et al. Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study. Neurobiol Dis. 2013; 51: 82-92. doi: 10.1016/j. nbd.2012.10.001.
52. Matsui JT, Vaidya JG, Johnson H.J., Magnotta VA, Long JD, Mlls JA, et al. Diffusion weighted imaging of prefrontal cortex in prodromal Huntington's disease. Hum Brain Mapp. 2013. doi: 10.1002/hbm. 22273.
53. Marrakchi-Kacem L., Delmaire C, Guevara P., Poupon F, Lecomte S, Tucholka A., et al. Mapping cortico-striatal connectivity onto the cortical surface: A new tractography-based approach to study Huntington disease. PloS One. 2013; 8(2): e53135. doi: 10.1371/journal.pone.0053135.
54. Buijink AW, Caan MW, Tijssen M.A., Hoogduin JM, Maurits NM, van Rootselaar AF Decreased cerebellar fiber density in cortical myoclonic tremor but not in essential tremor. Cerebellum. 2013; 12(2): 199-204. doi: 10.1007/s12311-012-0414-2.
55. Neychev VK Gross RE, Lehericy S, Hess E.J., Jinnah HA. The functional neuroanatomy of dystonia. Neurobiol Dis. 2011; 42(2): 185-201. doi: 10.1016/j.nbd.2011.01.026. This review describes current thinking regarding the neuroanatomic substrates of dystonia, and provides as a critical appraisal of the evidence from pathology, imaging (including diffusion MRI), and physiologic studies.
56. Zoons E, Booij J, Nederveen A.J., Dijk JM, Tijssen MA. Structural, functional and molecular imaging of the brain in primary focal dystonia - a review. Neuroimage. 2011; 56(3): 1011-20. doi: 10. 1016/j.neuroimage.2011.02. 045. This extensive review focuses on the role of neuroimaging specifically in focal dystonia, and includes descriptions of many of the important studies published prior to those listed in Table 2.
57. Niethammer M, Carbon M, Argyelan M., Eidelberg D. Hereditary dystonia as a neurodevelopmental circuit disorder: evidence from neuroimaging. Neurobiol Dis. 2011; 42(2): 202-9. doi: 10.1016/j. nbd.2010.10.010.
58. Carbon M, Kingsley PB, Su S, Smith G.S., Spetsieris P., Bressman S, et al. Mcrostructural white matter changes in carriers of the DYT1 gene mutation. Ann Neurol. 2004; 56(2): 283-6. doi: 10.1002/ana.20177. (Pubitemid 39037924)
59. Carbon M, Kingsley PB, Tang C, Bressman S., Eidelberg D. Microstructural white matter changes in primary torsion dystonia. Mov Disord. 2008; 23(2): 234-9. doi: 10.1002/mds.21806. (Pubitemid 351311553)
60. Ulug AM, Vo A, Argyelan M., Tanabe L, Schiffer WK, Dewey S, et al. Cerebellothalamocortical pathway abnormalities in torsin a DYT1 knock-in mice. Proc Natl Acad Sci USA. 2011; 108(16): 6638-43. doi: 10.1073/pnas.1016445108. This animal model of dystonia study is important because it demonstrated cerebellothalamic diffusion MRI changes in mutants compared with controls that correlated with measures of cortical metabolic activity, somewhat similar to the findings of Argyelan et al. [27].
61. Colosimo C, Pantano P, Calistri V., Totaro P, Fabbrini G, Berardelli A. Diffusion tensor imaging in primary cervical dystonia. J Neurol Neurosurg Psychiatry. 2005; 76(11): 1591-3. doi: 10.1136/jnnp.2004.056614. (Pubitemid 41531715)
62. Fabbrini G, Pantano P, Totaro P., Calistri V, Colosimo C, Carmellini M., et al. Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm. Eur J Neurol. 2008; 15(2): 185-9. doi: 10.1111/j. 1468-1331.2007.02034.x.
63. Bonilha L, de Vries PM, Vincent DJ, Rorden C, Morgan PS, Hurd M.W., et al. Structural white matter abnormalities in patients with idiopathic dystonia. Mov Disord. 2007; 22(8): 1110-6. doi: 10.1002/mds.21295. (Pubitemid 47067220)
64. Bonilha L, de Vries PM, Hurd MW, Rorden C, Morgan PS, Besenski N, et al. Disrupted thalamic prefrontal pathways in patients with idiopathic dystonia. Parkinsonism Relat Disord. 2009; 15(1): 64-7. doi: 10.1016/j.parkreldis.2008.01. 018.
65. Delmaire C, Vidailhet M, Wassermann D., Descoteaux M, Valabregue R, Bourdain F., et al. Diffusion abnormalities in the primary sensorimotor pathways in writer's cramp. Arch Neurol. 2009; 66(4): 502-8. doi: 10.1001/archneurol. 2009.8.
66. Simonyan K, Tovar-Moll F, Ostuni J., Hallett M, Kalasinsky VF, Lewin-Smith MR, et al. Focal white matter changes in spasmodic dysphonia: A combined diffusion tensor imaging and neuropatho-logical study. Brain. 2008; 131(2): 447-59. doi: 10.1093/brain/awm303. (Pubitemid 351197613)
67. Blood AJ. New hypotheses about postural control support the notion that all dystonias are manifestations of excessive brain postural function. Biosci Hypotheses. 2008; 1(1): 14-25. doi: 10.1016/j. bihy.2008.01.006.
68. Blood AJ, Tuch DS, Makris N, Makhlouf M.L., Sudarsky LR, Sharma N. White matter abnormalities in dystonia normalize after botulinum toxin treatment. Neuroreport. 2006; 17(12): 1251-5. doi: 10.1097/01.wnr.0000230500.03330.01. (Pubitemid 44337061)
69. Georgiou-Karistianis N., Scahill R, Tabrizi S.J., Squitieri F., Aylward E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev. 2013; 37(3): 480-90. doi: 10.1016/j.neubiorev.2013.01.022.
70. Paulsen JS, Langbehn DR, Stout J.C., Aylward E., Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008; 79(8): 874-80. doi: 10.1136/jnnp.2007.128728.
71. Tabrizi SJ, Reilmann R, Roos R.A., Durr A., Leavitt B, Owen G, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012; 11(1): 42-53. doi: 10.1016/S1474-4422(11)70263-0.
72. Kloppel S, Henley SM, Hobbs N.Z., Wolf RC, Kassubek J, Tabrizi SJ, et al. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience. 2009; 164(1): 205-19. doi: 10.1016/j.neuroscience.2009.01. 045.
73. Rosas HD, Koroshetz WJ, Chen Y.I., Skeuse C., Vangel M, Cudkowicz ME, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003; 60(10): 1615-20. (Pubitemid 36618087)
74. Mascalchi M, Lolli F, Della Nave R, Tessa C, Petralli R., Gavazzi C, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology. 2004; 232(3): 867-73. doi: 10.1148/radiol.2322030820. (Pubitemid 39100275)
75. Reading SA, Yassa MA, Bakker A, Dziorny A.C., Gourley LM, Yallapragada V, et al. Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study. Psychiatry Res. 2005; 140(1): 55-62. doi: 10.1016/j.pscychresns.2005.05.011. (Pubitemid 41443496)
76. Rosas HD, Tuch DS, Hevelone N.D., Zaleta AK, Vangel M, Hersch SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006; 21(9): 1317-25. doi: 10.1002/mds. 20979. (Pubitemid 44613279)
77. Seppi K, Schocke MF, Mair K.J., Esterhammer R., Weirich-Schwaiger H, Utermann B, et al. Diffusion-weighted imaging in Huntington's disease. Mov Disord. 2006; 21(7): 1043-7. doi: 10. 1002/mds.20868. (Pubitemid 44184612)
78. Magnotta VA, Kim J, Koscik T., Beglinger LJ, Espinso D, Langbehn D, et al. Diffusion tensor imaging in preclinical Huntington's disease. Brain Imaging Behav. 2009; 3(1): 77-84. doi: 10.1007/s11682-008-9051-2.
79. Stoffers D, Sheldon S, Kuperman J.M., Goldstein J., Corey-Bloom J, Aron AR. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology. 2010; 74(15): 1208-16. doi: 10.1212/WNL. 0b013e3181d8c20a
80. Rosas HD, Lee SY, Bender A.C., Zaleta AK, Vangel M, Yu P, et al. Altered white matter micro structure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage. 2010; 49(4): 2995-3004. doi: 10.1016/j.neuroimage.2009.10.015.
81. Muller HP, Glauche V, Novak M.J., Nguyen-Thanh T, Unrath A, Lahiri N., et al. Stability of white matter changes related to Huntington's disease in the presence of imaging noise: A DTI study. PLoS Curr. 2011; 3, RRN1232. doi: 10.1371/currents.RRN1232.
82. Bohanna I, Georgiou-Karistianis N, Sritharan A., Asadi H, Johnston L, Churchyard A., et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 2011; 5(3): 171-80. doi: 10.1007/s11682-011-9121-8.
83. Esmaeilzadeh M, Ciarmiello A, Squitieri F Seeking brain bio-markers for preventive therapy in Huntington disease. CNS Neurosci Ther. 2011; 17(5): 368-86. doi: 10.1111/j. 1755-5949.2010. 00157.x. This review highlights the neuroimaging literature (including diffusion MRI) and details the findings of previous studies aimed at developing imaging-based potential biomarkers for HD, and includes an interesting figure highlighting potential biomarkers according to each period of disease progression.
84. Weaver KE, Richards TL, Liang O, Laurino M.Y., Samii A., Aylward EH. Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol. 2009; 216(2): 525-9. doi: 10.1016/j.expneurol.2008.12.026.
85. Sritharan A, Egan GF, Johnston L, Horne M., Bradshaw JL, Bohanna I, et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry. 2010; 81(3): 257-62. doi: 10.1136/jnnp.2007.142786.
86. Della Nave R., Ginestroni A, Tessa C., Giannelli M, Piacentini S, Filippi M., et al. Regional distribution and clinical correlates of white matter structural damage in Huntington disease: A tract-based spatial statistics study. AJNR Am J Neuroradiol. 2010; 31(9): 1675-81. doi: 10.3174/ajnr.A2128.
87. Kloppel S, Draganski B, Golding C.V., Chu C., Nagy Z, Cook PA, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain. 2008; 131(1): 196-204. doi: 10.1093/brain/awm275.
88. Tan L, Yu JT, Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012; 323(1-2): 1-8. doi: 10.1016/j.jns.2012.08.005.
89. Blockx I, Van Camp N, Verhoye M, Boisgard R., Dubois A, Jego B, et al. Genotype specific age related changes in a transgenic rat model of Huntington's disease. Neuroimage. 2011; 58(4): 1006-16. doi: 10.1016/j.neuroimage.2011.07. 007.
90. Rizk-Jackson A., Stoffers D, Sheldon S., Kuperman J, Dale A, Goldstein J., et al. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. Neuroimage. 2011; 56(2): 788-96. doi: 10.1016/j.neuroimage.2010.04. 273.
91. Bohanna I, Georgiou-Karistianis N, Hannan A.J., Egan GF. Magnetic resonance imaging as an approach towards identifying neuropatho-logical biomarkers for Huntington's disease. Brain Res Rev. 2008; 58(1): 209-25. doi: 10.1016/j.brainresrev.2008.04.001.
92. Ross CA, Tabrizi SJ. Huntington's disease: from molecular patho-genesis to clinical treatment. Lancet Neurol. 2011; 10(1): 83-98. doi: 10.1016/S1474-4422(10)70245-3.
93. Martinelli P, Rizzo G, Manners D., Tonon C, Pizza F, Testa C., et al. Diffusion-weighted imaging study of patients with essential tremor. Mov Disord. 2007; 22(8): 1182-5. doi: 10.1002/mds.21287. (Pubitemid 47067233)
94. Shin DH, Han BS, Kim H.S., Lee PH. Diffusion tensor imaging in patients with essential tremor. AJNR Am J Neuroradiol. 2008; 29(1): 151-3. doi: 10.3174/ajnr.A0744.
95. Nicoletti G, Manners D, Novellino F., Condino F, Malucelli E, Barbiroli B., et al. Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. Neurology. 2010; 74(12): 988-94. doi: 10.1212/WNL.0b013e3181d5a460.
96. Jia L, Jia-Lin S, Qin D., Qing L, Yan Z. A diffusion tensor imaging study in essential tremor. J Neuroimaging. 2011; 21(4): 370-4. doi: 10.1111/j.1552-6569.2010.00535.x.
97. Klein JC, Lorenz B, Kang J.S., Baudrexel S., Seifried C, van de Loo S, et al. Diffusion tensor imaging of white matter involvement in essential tremor. Hum Brain Mapp. 2011; 32(6): 896-904. doi: 10. 1002/hbm.21077.
98. Elble RJ. What is essential tremor? Curr Neurol Neurosci Rep. 2013; 13(6): 353. doi: 10.1007/s11910-013-0353-4.
99. Brunenberg EJ, Moeskops P, Backes W.H., Pollo C., Cammoun L, Vilanova A, et al. Structural and resting state functional connectivity of the subthalamic nucleus: identification of motor STN parts and the hyperdirect pathway. PloS One. 2012; 7(6): e39061. doi: 10.1371/journal.pone.0039061.
100. Sedrak M, Gorgulho A, Frew A., Behnke E, DeSalles A, Pouratian N. Diffusion tensor imaging and colored fractional anisotropy mapping of the ventralis intermedius nucleus of the thalamus. Neurosurgery. 2011; 69(5): 1124-9. doi: 10.1227/NEU. 0b013e3182296a42.discussion 1129-30
101. Kincses ZT, Szabo N, Valalik I., Kopniczky Z, Dezsi L, Klivenyi P., et al. Target identification for stereotactic thalamotomy using diffusion tractography. PloS One. 2012; 7(1): e29969. doi: 10.1371/journal.pone.0029969.
102. Pouratian N, Zheng Z, Bari A.A., Behnke E., Elias WJ, Desalles AA. Multi-institutional evaluation of deep brain stimulation targeting using probabilistic connectivity-based thalamic segmentation. J Neurosurg. 2011; 115(5): 995-1004. doi: 10.3171/2011.7.JNS11250.
103. Elias WJ, Zheng ZA, Domer P, Quigg M., Pouratian N. Validation of connectivity-based thalamic segmentation with direct electrophysiologic recordings from human sensory thalamus. Neuroimage. 2012; 59(3): 2025-34. doi: 10.1016/j.neuroimage.2011.10.049.
104. Sudhyadhom A, McGregor K, Okun M.S., Foote KD, Trinastic J, Crosson B, et al. Delineation of motor and somatosensory thalamic subregions utilizing probabilistic diffusion tractography and elec-trophysiology. J Magn Reson Imaging. 2013; 37(3): 600-9. doi: 10. 1002/jmri.23861.
105. Henderson JM. "Connectomic surgery": diffusion tensor imaging (DTI) tractography as a targeting modality for surgical modulation of neural networks. Front Integr Neurosci. 2012; 6: 15. doi: 10.3389/fnint.2012.00015.
106. Klein JC, Barbe MT, Seifried C, Baudrexel S., Runge M, Maarouf M, et al. The tremor network targeted by successful VIM deep brain stimulation in humans. Neurology. 2012; 78(11): 787-95. doi: 10. 1212/WNL.0b013e318249f702. This study used probabilistic tractography to demonstrate structural connectivity between effective thalamic stimulation sites and areas of the brain known to be part of a tremor-generating network. This network was consistent across patients and was consistent with prior functional imaging studies and animal models.
107. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011; 10(6): 573-90. doi: 10. 1016/S1474-4422(11)70070-9.